XML 80 R136.htm IDEA: XBRL DOCUMENT
v3.20.1

Equity - Reserves - Subsidiaries (Details) € in Thousands, EquityInstruments in Millions | 1 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
Dec. 31, 2019 EUR (€) EquityInstruments | Jul. 31, 2019 EUR (€) shares | Jun. 30, 2019 EUR (€) | Apr. 30, 2019 EUR (€) | Sep. 30, 2018 EUR (€) shares | Jun. 30, 2018 EUR (€) | Oct. 31, 2017 EUR (€) shares | Dec. 31, 2019 EUR (€) EquityInstruments shares | Dec. 31, 2018 EUR (€) | Dec. 31, 2017 EUR (€) | Aug. 31, 2018 | May 31, 2018 | Sep. 30, 2017
Equity |  |  |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) in working capital |  |  |  |  |  |  |  | € 481,537 | € 112,639 | € 65,800 |  |  |
Increase (decrease) in reserves |  |  |  |  |  |  |  | 1,716,147 | € 465,548 | € (389) |  |  |
Reserves |  |  |  |  |  |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) in reserves |  |  |  |  |  |  |  | € 227,000 |  |  |  |  |
Araclon Biotech , S.L |  |  |  |  |  |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |  |  |  |  |  |
share capital increases | € 5,900 |  |  | € 16,800 |  |  |  |  |  |  |  |  |
Grifols [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |  |  |  |  |  |
Indirect (as a percent) |  |  |  | 75.10% |  |  |  |  |  |  |  |  |
Progenika Biopharma, S.A. |  |  |  |  |  |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |  |  |  |  |  |
Increased capital |  | € 4 |  |  | € 4,333 |  |  |  |  |  |  |  |
Acquired Capital (in shares) | shares |  | 33 |  |  | 41,387 |  | 12,020 |  |  |  |  |  |
Indirect (as a percent) |  | 100.00% | 99.99% |  | 99.99% |  | 90.23% |  |  |  | 96.64% |  | 89.25%
Increase (decrease) in reserves |  |  |  |  |  |  | € (374,000) |  |  |  |  |  |
TiGenix | Reserves |  |  |  |  |  |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |  |  |  |  |  |
Increase in reserves due to divestment |  |  |  |  |  | € 4,900 |  |  |  |  |  |  |
TiGenix | Other comprehensive income |  |  |  |  |  |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |  |  |  |  |  |
Decrease in other comprehensive income |  |  |  |  |  | 4,900 |  |  |  |  |  |  |
Ekarpen Private Equity, S.A |  |  |  |  |  |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |  |  |  |  |  |
Increased capital |  |  |  |  |  | € 5,300 |  |  |  |  |  |  |
Indirect (as a percent) |  |  |  |  |  | 96.64% |  |  |  |  |  | 90.23% |
Additional stake acquired (as a percent) |  |  |  |  |  | 6.41% |  |  |  |  |  |  |
Kiro Grifols [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) in working capital |  |  | € 7,500 |  |  |  |  |  |  |  |  |  |
Proportion of ownership interests held by non-controlling interests |  |  | 90.00% |  |  |  |  |  |  |  |  |  |
Proportion of voting rights held by non-controlling interests |  |  | 10.00% |  |  |  |  |  |  |  |  |  |
GDS Group |  |  |  |  |  |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired Capital (in shares) | shares |  |  |  |  |  |  |  | 90 |  |  |  |  |
Increase (decrease) in reserves |  |  |  |  |  |  |  | € 227,000 |  |  |  |  |
Consideration transferred, in shares | EquityInstruments | 1,766 |  |  |  |  |  |  | 1,766 |  |  |  |  |
Shanghai RAAS Blood Products, Co. Ltd. |  |  |  |  |  |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired Capital (in shares) | shares |  |  |  |  |  |  |  | 0 |  |  |  |  |

X
- Definition The number of shares acquired. + References No definition available. + Details
Name: | grfs_AcquisitionOfCapital
Namespace Prefix: | grfs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase (decrease) in other comprehensive income due to divestment in subsidiary or investment. + References No definition available. + Details
Name: | grfs_IncreaseDecreaseInOtherComprehensiveIncomeDueToDivestmentInSubsidiaryOrInvestment
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) in reserves due to divestment in subsidiary or investment. + References No definition available. + Details
Name: | grfs_IncreaseDecreaseInReservesDueToDivestmentInSubsidiaryOrInvestment
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The proportion of indirect ownership interest in a subsidiary attributable to the entity. + References No definition available. + Details
Name: | grfs_ProportionOfOwnershipInterestInSubsidiaryIndirect
Namespace Prefix: | grfs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Subsidiaries, increased capital. + References No definition available. + Details
Name: | grfs_SubsidiariesIncreasedCapital
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) in equity. [Refer: Equity] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 106 -Subparagraph d -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_106_d&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ChangesInEquity
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase (decrease) in working capital. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 7 -IssueDate 2019-01-01 -Paragraph 20 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2019-en-r&anchor=para_20&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_IncreaseDecreaseInWorkingCapital
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 106 -Subparagraph d -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_106_d_iii&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph f -Clause iv -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_PercentageOfVotingEquityInterestsAcquired
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph 12 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_12_c&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of the voting rights in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph 12 -Subparagraph d -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_12_d&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ProportionOfVotingRightsHeldByNoncontrollingInterests
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_AraclonBiotechS.lMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_GrifolsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_ProgenikaBiopharmaSaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_TigenixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=grfs_MiscellaneousOtherComprehensiveIncomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_EkarpenPrivateEquityS.aMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_KiroGrifolsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_GrifolsDiagnosticsSolutionsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_ShanghaiRaasBloodProductsCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |